Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lubion is a brand name for a specific aqueous solution of progesterone (25 mg) designed for subcutaneous injection, primarily used for luteal phase support in women undergoing assisted reproductive technology (ART). Developed by IBSA Institut Biochimique SA, the formulation utilizes hydroxypropyl-β-cyclodextrin (HPBCD) to enhance the solubility of the lipophilic progesterone molecule in water. This innovation allows for subcutaneous self-administration, providing a more patient-friendly alternative to traditional oil-based intramuscular progesterone injections, which are often associated with injection site pain, sterile abscesses, and the requirement for professional administration. Progesterone is a naturally occurring steroid hormone that binds to the progesterone receptor, inducing the secretory transformation of the endometrium to facilitate embryo implantation and support the maintenance of early pregnancy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lubion (progesterone).